Fidelity Investments
RNAZ icon

Fidelity Investments’s TransCode Therapeutics RNAZ Stock Holding History

Fidelity Investments’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.38K Buy
+706
New +$4.8K ﹤0.01% 5043
2025
Q3 		– Sell
-3
Closed -$23 – 5553
2025
Q2 		$23 Buy
3
+2
+200% +$19 ﹤0.01% 5260
2025
Q1 		$12 Buy
+1
New +$128 ﹤0.01% 5243
2024
Q4 		– Hold
0
– -$100 – 5774
2024
Q3 		– Hold
0
– – – 5096

Other funds holding RNAZ

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Fidelity Investments's RNAZ Position: Q2 2026 in Review

Fidelity Investments opened a new position in TransCode Therapeutics (RNAZ) in Q2 2026: 706 shares worth $4.38K. The stake represents ﹤0.01% of the portfolio and ranks #5043 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in RNAZ as recently as Q2 2025.

Fidelity Investments first reported a position in RNAZ in Q1 2025 and has held it in 3 quarters since. 8 funds tracked by Wall St. Rank hold RNAZ as of Q2 2026.

  • Fidelity Investments held 706 shares of TransCode Therapeutics worth $4.38K as of Q2 2026.
  • TransCode Therapeutics was a new Fidelity Investments position in Q2 2026.
  • TransCode Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5043 holding.
  • Fidelity Investments first reported a position in TransCode Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.